# SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

> **NCT06149793** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Minnesota** · enrollment: 8 (actual)

## Conditions studied

- Cystic Fibrosis-related Diabetes
- Cystic Fibrosis

## Interventions

- **DRUG:** Empagliflozin
- **OTHER:** Placebo Control

## Key facts

- **NCT ID:** NCT06149793
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-08
- **Primary completion:** 2025-06-03
- **Final completion:** 2026-12-31
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06149793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06149793, "SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06149793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*